Cormorant Asset Management, LP X4 Pharmaceuticals, Inc Transaction History

Cormorant Asset Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.69 - $2.21 $550,844 - $1.76 Million	798,326 Added 96.11%	1,628,980 $1.62 Million
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.71 $646,739 - $1.24 Million	726,674 Added 698.86%	830,654 $1.42 Million
Q4 2020 Feb 16, 2021	BUY	$5.41 - $7.4 $562,531 - $769,452	103,980 New	103,980 $669,000
Q3 2020 Nov 16, 2020	SELL	$6.09 - $9.15 $2 Million - $3.01 Million	-328,980 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$7.98 - $10.44 $100,851 - $131,940	-12,638 Reduced 3.7%	328,980 $1.76 Million
Q1 2020 May 15, 2020	BUY	$6.03 - $11.01 $535,892 - $978,469	88,871 Added 35.16%	341,618 $3.42 Million
Q4 2019 Feb 14, 2020	SELL	$9.93 - $14.33 $6.25 Million - $9.01 Million	-628,934 Reduced 71.33%	252,747 $2.7 Million
Q3 2019 Nov 14, 2019	SELL	$11.06 - $15.75 $96,288 - $137,119	-8,706 Reduced 0.98%	881,681 $11.2 Million
Q2 2019 Aug 14, 2019	BUY	$12.57 - $21.67 $8.02 Million - $13.8 Million	637,638 Added 252.28%	890,387 $13.4 Million
Q1 2019 May 15, 2019	BUY	$15.19 - $22.98 $3.84 Million - $5.81 Million	252,749 New	252,749 $4.4 Million

105

100M

213K

50.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.